Cetera Investment Advisers
REGN icon

Cetera Investment Advisers’s Regeneron Pharmaceuticals REGN Stock Holding History

Cetera Investment Advisers’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.96K Buy
+100
New +$76.6K ﹤0.01% 4715

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Cetera Investment Advisers's REGN Position: Q1 2026 in Review

Cetera Investment Advisers increased its Regeneron Pharmaceuticals (REGN) stake by 1.3% in Q1 2026, buying an estimated $152K and bringing the position to 16,006 shares worth $12.4M. The position accounts for 0.01% of the portfolio, ranked #950.

Cetera Investment Advisers first reported a position in REGN in Q4 2020 and has held it in 22 quarters since. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Cetera Investment Advisers held 16,006 shares of Regeneron Pharmaceuticals worth $12.4M as of Q1 2026.
  • Cetera Investment Advisers bought 198 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $152K.
  • Regeneron Pharmaceuticals made up 0.01% of Cetera Investment Advisers's portfolio in Q1 2026, its #950 holding.
  • Cetera Investment Advisers first reported a position in Regeneron Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.